Insulet recently announced that its Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring System, enhancing its Automated Insulin Delivery capabilities. Over the ...
Insulet (NASDAQ:PODD) has received FDA clearance for an iPhone app for its Omnipod 5 insulin delivery system. The company said the approval makes Insulet the first company to offer a tubeless ...
Zacks Investment Research on MSN
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
Insulet PODD has seen impressive momentum in the past year, with its shares soaring 37.4%. It has significantly outperformed the industry’s 0.5% fall and the S&P 500 composite’s 17.5% gain. Presently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback